A new partnership between the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute and ARcare aims to improve colorectal cancer screening rates in seven rural Arkansas counties where late-stage diagnoses and cancer disparities are on the rise.
Zhan, seated, with Steven Webber (left), dean of the College of Medicine and executive vice chancellor at UAMS, and UAMS chancellor Cam Patterson (right).The University of Arkansas for Medical Sciences College of Medicine invested Fenghuang “Frank” Zhan, a tenured professor of medicine and the research director of the UAMS Winthrop P. Rockefeller Cancer Institute’s Myeloma Center, in the Bart Barlogie Chair for Myeloma Research during a March 13 ceremony.
The EU has approved Sarclisa (isatuximab-irfc) in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant, based on data from the IMROZ phase III study.
Northwell Health appointed David J. Chung, a prominent oncologist-investigator, as director of clinical research at the Northwell Health Cancer Institute. In this newly created role, Chung also will serve as system chief of multiple myeloma across Northwell’s cancer centers.
Johnson & Johnson announced new frontline data featuring Tecvayli (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma in induction and maintenance settings.
GSK plc announced statistically significant and clinically meaningful overall survival results from a planned interim analysis of the DREAMM-7 trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone versus daratumumab in combination with bortezomib plus dexamethasone as a second line or later treatment for relapsed or refractory multiple myeloma.
Johnson & Johnson announced new results from the phase III CARTITUDE-4 study that show a single infusion of Carvykti (ciltacabtagene autoleucel; cilta-cel) significantly increased minimal residual disease negativity rates (10-5) in patients with relapsed or refractory multiple myeloma who were lenalidomide-refractory and had received one to three prior lines of therapy, including a proteasome inhibitor, compared to standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.
Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, a treatment for multiple myeloma. Their study was published this month in the journal Blood Neoplasia.
Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.
FDA approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.
